We are live on ! Find out more
IPXL

Impax Laboratories, Inc.
IPXL

Delisted

IPXL was delisted on the 4th of May, 2018.

158 hedge funds and large institutions have $1.14B invested in Impax Laboratories, Inc. in 2013 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 57 increasing their positions, 57 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

127% more call options, than puts

Call options by funds: $4.27M | Put options by funds: $1.88M

67% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 15

6% more funds holding

Funds holding: 149158 (+9)

2% more capital invested

Capital invested by funds: $1.12B → $1.14B (+$20.5M)

0% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 57

67% less funds holding in top 10

Funds holding in top 10: 31 (-2)

Holders
158
Holders Change
+9
Holders Change %
+6.04%
% of All Funds
5.12%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.03%
New
25
Increased
57
Reduced
57
Closed
15
Calls
$4.27M
Puts
$1.88M
Net Calls
+$2.39M
Net Calls Change
+$5.85M
Name Holding Trade Value Shares
Change
Change in
Stake
EMG
101
Ellington Management Group
Connecticut
$721K -$318K -15,400 -30%
Axa
102
Axa
France
$654K
HHC
103
Hutchin Hill Capital
New York
$602K -$171K -8,300 -22%
HighTower Advisors
104
HighTower Advisors
Illinois
$593K +$594K +28,770 New
Royal Bank of Canada
105
Royal Bank of Canada
Ontario, Canada
$592K -$19.9K -966 -3%
Goldman Sachs
106
Goldman Sachs
New York
$577K -$4.9M -237,304 -89%
Citigroup
107
Citigroup
New York
$533K -$137K -6,630 -20%
DC
108
Deere & Company
Illinois
$526K -$59.9K -2,901 -10%
Thrivent Financial for Lutherans
109
Thrivent Financial for Lutherans
Minnesota
$477K -$12.4K -600 -3%
RFC
110
Russell Frank Company
Washington
$472K +$406K +19,675 +589%
Fifth Third Bancorp
111
Fifth Third Bancorp
Ohio
$467K -$15.9K -772 -3%
SG Americas Securities
112
SG Americas Securities
New York
$466K +$469K +22,726 New
Envestnet Asset Management
113
Envestnet Asset Management
Illinois
$457K +$805 +39 +0.2%
Public Employees Retirement Association of Colorado
114
Public Employees Retirement Association of Colorado
Colorado
$431K
B
115
Baird
Wisconsin
$417K -$3.53K -171 -0.8%
GMIM
116
General Motors Investment Management
New York
$416K +$71.1K +3,444 +20%
PA
117
Profund Advisors
Maryland
$410K +$61K +2,952 +17%
GT
118
Glenmede Trust
Pennsylvania
$402K
NI
119
Numeric Investors
Massachusetts
$387K -$72.3K -3,500 -16%
CCIA
120
Campbell & Co Investment Adviser
Maryland
$383K +$387K +18,732 New
BNP Paribas Financial Markets
121
BNP Paribas Financial Markets
France
$382K -$113K -5,450 -23%
MAA
122
Managed Account Advisors
New Jersey
$381K -$58.3K -2,823 -13%
T. Rowe Price Associates
123
T. Rowe Price Associates
Maryland
$361K
PP
124
Paloma Partners
Connecticut
$355K +$357K +17,300 New
IRS
125
Invictus RG (Singapore)
Singapore
$349K +$352K +17,040 New

IPXL Hedge Fund Activity: Q3 2013 in Review

158 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Impax Laboratories, Inc. (IPXL) for Q3 2013, worth a combined $1.14B — up 1.8% from $1.12B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new IPXL positions and 15 closed out — a net gain of 10 holders — while 57 added to existing stakes and 57 trimmed.

The largest buyer was Tradewinds Global Investors, opening a new position worth an estimated $13.9M. The largest seller was Apex Capital, cutting an estimated $23.1M.

  • 158 institutional investors held Impax Laboratories, Inc. (IPXL) as of Q3 2013, up from 149 in Q2 2013.
  • Funds reported $1.14B of Impax Laboratories, Inc. stock for Q3 2013, up 1.8% quarter-over-quarter.
  • 25 funds opened new Impax Laboratories, Inc. positions in Q3 2013 and 15 closed out, a net change of +10 holders.
  • The largest Impax Laboratories, Inc. buyer in Q3 2013 was Tradewinds Global Investors, an estimated $13.9M added.
  • The largest Impax Laboratories, Inc. seller in Q3 2013 was Apex Capital, an estimated $23.1M sold.

Based on aggregated 13F filings for Q3 2013.